Publication:
Gonadotropin-releasing hormone agonist treatment and ischemic heart disease among female patients with breast cancer: A cohort study

Simple item page
cris.lastimport.scopus2026-02-23T16:03:25Z
dc.creatorChou, Yi-Sheng
dc.creatorWang, Chun-Chieh
dc.creatorHsu, Li-Fei
dc.creatorChuang, Pei-Hung
dc.creatorCheng, Chi-Feng
dc.creatorLi, Nai-Hsin
dc.creatorChen, Chu-Chieh
dc.creatorChen, Chien-Liang
dc.creatorLai, Yun-Ju
dc.creatorYen, Yung-Feng
dc.date2022-10
dc.date.accessioned2023-05-03T02:23:36Z
dc.date.accessioned2025-07-28T15:04:45Z
dc.date.available2023-05-03T02:23:36Z
dc.date.issued2023-05-03T02:23:36Z
dc.description.abstractBackground The risk of ischemic heart disease (IHD) due to the impact of gonadotropin-releasing hormone (GnRH) agonists among female patients with breast cancer remains a controversy. Methods Information from the Registry for Catastrophic Illness, the National Health Insurance Research Database (NHIRD), and the Death Registry Database in Taiwan were analyzed. Female patients with breast cancer were selected from the Registry for Catastrophic Illness from January 1, 2000, to December 31, 2018. All the breast cancer patients were followed until new-onset IHD diagnosis, death, or December 31, 2018. A Kaplan-Meier survival curve was drawn to show the difference between patients treated with and without GnRH agonists. The Cox regression analysis was used to investigate the effects of GnRH agonists and the incidence of IHD. Results A total of 172,850 female patients with breast cancer were recognized with a mean age of 52.6 years. Among them, 6071(3.5%) had received GnRH agonist therapy. Kaplan-Meier survival curves showed a significant difference between patients with and without GnRH therapy (log-rank p < 0.0001). Patients who received GnRH therapy had a significantly decreased risk of developing IHD than those without GnRH therapy (HR = 0.18; 95% CI = 0.14-0.23). After adjusting for age, treatment, and comorbidity, patients who received GnRH therapy still had a significantly lower risk of developing IHD (AHR = 0.5, 95% CI = 0.39-0.64). Conclusion The study showed that the use of GnRH agonists for breast cancer treatment was significantly associated with a reduced risk of IHD. Further research is required to investigate the possible protective effect of GnRH on IHD.
dc.format.extent99 bytes
dc.format.mimetypetext/html
dc.identifier.doi10.1002/cam4.5390
dc.identifier.issn2045-7634
dc.identifier.urihttps://ir.ntus.edu.tw/handle/987654321/65638
dc.languageen_US
dc.publisherNEW YORK: WILEY
dc.relationCANCER MEDICINE, 12(5)
dc.subjectbreast neoplasms
dc.subjectcardiovascular diseases
dc.subjectgonadotropin-releasing hormone
dc.subjectheart disease risk factors
dc.subjectmyocardial ischemia
dc.titleGonadotropin-releasing hormone agonist treatment and ischemic heart disease among female patients with breast cancer: A cohort study
dc.typearticle
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
index.html
Size:
99 B
Format:
Hypertext Markup Language
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
702 B
Format:
Plain Text
Description:
Download

Collections

期刊論文